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Synthesis of Activatable MR Prodrug and Scheme for the mechanism of activation of Prodrug
Figure 1: (A) The Schematic diagram for the proposed 
mechanism of nanomedicine formulated from ICAM1 
functionalized nanoceria using a doxorubicin-gadolinium complex 
as a prodrug to treat TNBC.
Cell Internalization studies:
Figure 3: (A – D) Characterization studies of doxorubicin-loaded, ICAM1-
functionalized Nanoceria (8) where (A), (B), (C), (D) represents size, zeta 
potential, UV absorbance and fluorescence, respectively. (E-H) 
Characterization studies of prodrug-loaded, ICAM1-functionalized Nanoceria 
(10) following the same order.
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Scheme 1: Synthesis of activatable Doxo-Gd prodrug. 
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Synthesis and Functionalization of Nanoceria (NC):
Scheme 2: Stepwise synthesis of ICAM1-functionalized (6), 
drug (7)/prodrug (9)-loaded, and ICAM1-functionalized drug 
(8)/prodrug (10)-loaded Nanoceria.
Figure 4: Cytotoxicity assay showing the effectiveness of our Nanoceria-based drug delivery 
system against the MDA-MB-231 cell line (TNBC) (A) and the MCF-7 breast cancer cell line (B). 
Experiments were done in triplicate and calculated against standard error. 
In-vitro Cell viability (MTT assay): 
Figure 7: Determination (A – H) and quantification (I) of cytoplasmic ROS generation in 
TNBC cells (scale bar 500 μm). (A – B) Generation of ROS after treatment with PNC-
ICAM1 (6), (C – D) generation of ROS after treatment with PNC-Doxo-ICAM1 (8), (E – F) 
generation of ROS after treatment with PNC-Doxo-Gd-ICAM1 (10), and (G – H) 
generation of ROS after treatment with H2O2, all labeled with DHE dye. (I) Each trial was 
performed in triplicate and the level of ROS generation was quantified directly from the 
corresponding fluorescence images using ImageJ software.
Figure 5: (A – D) Internalization of PNC-ICAM1 (6) in TNBC cells was observed after 24 h, due 
to ICAM1-receptor-mediated endocytosis (scale bar 500 μm). (E – H) Internalization of PNC-
Doxo-ICAM1 (8) was also identified in TNBC cells after 24 h with cell morphology indicating 
cellular stress. (I – L) Internalization of PNC-Doxo-Gd-ICAM1 (10) was also detected in TNBC 
cells after 24 h with cell morphology pointing to cellular stress. Negligible internalization of PNC-
Doxo-Gd-ICAM1 (10) was observed in MCF-7 cells demonstrating the effectiveness of the ICAM1 
antibody as a ligand to target ICAM1-overexpressed cancer cells. Nuclei stained with DAPI (blue).
Figure 8: Comet assays performed on TNBC (A – B) and MCF-7 (C – D) cell lines after 
incubation with PNC formulations 8 (A and C), and 10 (B and D).
Figure 6: (A – D) Internalization of PNC-ICAM1 (6) in TNBC cells was observed after 48 h, due to 
ICAM1-receptor-mediated endocytosis (scale bar 500 μm). (E – H) Internalization of PNC-Doxo-
ICAM1 (8) was also identified in TNBC cells after 48 h with cell morphology pointing to cell death. (I –
L) Internalization of PNC-Doxo-Gd-ICAM1 (10) was also detected in TNBC cells after 48 h with cell 
morphology indicating cell death. Minimal internalization of PNC-Doxo-Gd-ICAM1 (10) was observed 
in MCF-7 cells (attributed to nonspecific internalization) demonstrating the effectiveness of the 
ICAM1 antibody as a ligand to target ICAM1-overexpressed cancer cells. Nuclei stained with DAPI 
(blue).
Characterization of the activatable probe:
Conclusion
A doxorubicin/gadolinium-based prodrug was successfully synthesized by using a cleavable 
crosslinker to join doxorubicin and gadolinium chelated with an aminobenzyl derivative of 
DTPA. Quantitative internalization and cell viability studies proved our ICAM1-functionalized 
Nanoceria is selective to and successfully kills TNBC cells within 48 hours, which was 
visualized by fluorescence microscopy. ROS assays correlated with cell viability studies 
showing high levels of ROS where cell viability was the lowest. Finally, results from the comet 
assay further demonstrated that our prodrug (4) activates intracellularly by GSH mediated 
cleavage, releasing doxorubicin and generating DNA damage. Our results show the 
simultaneous selective delivery, chemotherapy, MR imaging and tumor tracking overcome the 
limitations of single modality treatments by providing valuable theranostic attributes for a 
physician in a single treatment, with the highest potential impact to the patient who could 
potentially experience less side effects by selective delivery and go through fewer injections 
due to the combination prodrug therapy.
Figure 2: (A) Absorbance, (B) florescence, and (C) 
MALDI-TOF chromatogram showing molecular weight of 
our Doxo-Gd activatable prodrug (4)
ABSTRACT
In this study, a new multimodal theranostic tool is
reported utilizing nanoceria delivery system
conjugated with the ICAM1 antibody and a
magnetic resonance (MR) probe as a prodrug with
both MR and cytotoxic properties. The prodrug
was synthesized from doxorubicin and phenyl-
amine modified DTPA chelated with gadolinium
utilizing dithiobis(succinimidyl propionate) (DSP)
as a crosslinker. Nanoceria was synthesized from
cerium oxide and polyacrylic acid using a water-
based alkali precipitation technique. Doxorubicin
and the synthesized prodrug were encapsulated
separately within the nanoceria polymer matrix
using a solvent diffusion method. The
drug/prodrug-encapsulated nanoceria’s
carboxylated surface was functionalized with the
ICAM1 antibody utilizing EDC/NHS chemistries
and the resulting formulations were purified and
characterized by DLS, zeta potential, UV/Vis, and
MR. The efficacy of this platform was measured by
treating MDA-MB-231 breast cancer (TNBC) cells
and MCF-7 cells with the drug/prodrug-loaded,
ICAM1-conjugated nanoceria and analyzing the
results of the treatment. Results were evaluated by
cytotoxicity assays (MTT), fluorescence
microscopy, reactive oxygen species
determination, and comet assays. In all, the results
show the nanoceria platform is target-specific to
TNBC, and the encapsulated prodrug is able to be
activated releasing doxorubicin and initiating
apoptosis in an in vivo breast cancer model.
INTRODUCTION
The need for new, multimodal therapies is of
huge diagnostic and therapeutic importance to the
field of oncology. When a patient is diagnosed with
cancer, the identification and time to treatment has
a significant impact on prognosis due to the
aggressiveness and treatability of some cancers.
Specifically, triple negative breast cancer (TNBC)
poses a unique problem due to its aggressiveness.
In addition, the lack of hormone epidermal growth
factor receptor 2 (HER-2), estrogen receptors, and
progesterone receptors make it more difficult to
treat since common hormone therapies and drugs
that target HER-2, estrogen, and progesterone are
not effective. At this time, radiotherapy,
chemotherapy, and high intensity focused
ultrasound have been used extensively,
successfully suppressing tumors and extending
the lives of patients. However, a single method of
treatment is often not able to completely eliminate
cancer or prevent metastasis due to multidrug
resistance in long-term therapies. In the interest of
developing a multimodal therapy for cancer
treatment, we continued to investigate the
capabilities of polyacrylic acid (PAA)-coated
nanoceria (PNC) as a multimodal theranostic tool
for the detection and treatment of triple negative
breast cancer (TNBC). We synthesized PNC
nanoparticles and functionalized their surfaces
with the ICAM1 antibody to specifically target
MDA-MB-231 (TNBC) cells. To introduce
multimodality, we synthesized a prodrug with both
chemotherapeutic and magnetic resonance (MR)
properties as shown in Figure 1. We coupled the
chemotherapeutic drug doxorubicin with a phenyl-
amine modified diethylenetriamine pentaacetate
(DTPA) chelated with the T1 MR contrast agent
gadolinium using dithiobis(succinimidyl
propionate) (DSP) as the cross-linker. Using
doxorubicin and gadolinium as a combination
allows for simultaneous chemotherapy, MR
imaging, and tumor tracking; and when coupled
with targeted delivery it provides a valuable
multimodal theranostic tool to diagnose and treat
TNBC. In addition, this methodology can be
applied to other cancer cells by changing the
targeting ligand bound to the PNC nanoparticles.
In all, these traits make our PNC nanoparticle-
delivered prodrug a novel platform for a
multimodal approach to monitor and treat cancer.
Characterization of activatable NC:
Figure S2: Comparative study of average magnetic resonance 
data over three measurements showing T1 and T2 values of 
PNC-COOH (5), the synthesized Doxo-Gd prodrug (4), and the 
ICAM1 conjugated PNC with our Doxo-Gd prodrug encapsulated 
(10).
Mechanism of action of the proposed 
nanomedicine
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